CannTrust (OTCMKTS:CNTTF) versus Aadi Bioscience (NASDAQ:AADI) Head to Head Survey

Valuation and Earnings

This table compares CannTrust and Aadi Bioscience”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CannTrust	$15.96 million	0.00	$7.39 million	$0.07	N/A
Aadi Bioscience	$25.07 million	4.09	-$65.76 million	($2.35)	-1.77

CannTrust has higher earnings, but lower revenue than Aadi Bioscience. Aadi Bioscience is trading at a lower price-to-earnings ratio than CannTrust, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

0.1% of CannTrust shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk & Volatility

CannTrust has a beta of 4.52, indicating that its stock price is 352% more volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.

Profitability

This table compares CannTrust and Aadi Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CannTrust	N/A	N/A	N/A
Aadi Bioscience	-246.06%	-71.87%	-57.28%

Summary

CannTrust beats Aadi Bioscience on 7 of the 10 factors compared between the two stocks.

About CannTrust

CannTrust Holdings Inc. produces and distributes pharmaceutical grade medical cannabis products in Canada. It sells dried cannabis and oil extractions to the client based on the medication document provided by health care practitioner. The company has a partnership with Gold Coast University Hospital. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

About Aadi Bioscience

Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.